Last updated: February 19, 2026
Daprodustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is positioned to capture a significant share of the anemia market for patients with chronic kidney disease (CKD). The drug's development trajectory, regulatory approvals, and competitive landscape indicate a substantial revenue potential, though challenges related to safety profiles and market entry timelines persist.
What is Daprodustat's Mechanism of Action and Therapeutic Indication?
Daprodustat stimulates the body's natural response to low oxygen levels by inhibiting HIF-PH enzymes. This inhibition leads to the stabilization and activation of hypoxia-inducible factors (HIFs), which in turn upregulate the production of erythropoietin (EPO). Increased EPO stimulates the bone marrow to produce more red blood cells, thereby raising hemoglobin levels and improving anemia [1].
The primary therapeutic indication for daprodustat is the treatment of anemia due to CKD in adult patients. This includes both dialysis-dependent and non-dialysis-dependent CKD patients. The drug offers an oral alternative to injectable erythropoiesis-stimulating agents (ESAs), addressing a key unmet need for convenience and patient preference.
Which Companies are Involved in Daprodustat's Development and Commercialization?
GlaxoSmithKline (GSK) is the primary developer and commercializing entity for daprodustat. The company has spearheaded its clinical development and regulatory submissions globally. In certain territories, GSK has established partnerships for distribution and marketing. For example, in Japan, GSK partnered with Nippon Shinyaku. In China, the drug is marketed by GSK in partnership with Simcere Pharmaceutical Group.
What is the Current Regulatory Status of Daprodustat?
Daprodustat has achieved significant regulatory milestones across major markets:
- United States: The U.S. Food and Drug Administration (FDA) rejected daprodustat in August 2020, citing safety concerns related to cardiovascular events in patients with CKD not on dialysis. GSK has been engaged in further discussions with the FDA regarding a potential resubmission.
- Europe: The European Medicines Agency (EMA) approved daprodustat (marketed as Jynarque) in March 2020 for the treatment of symptomatic anemia due to chronic kidney disease in adult patients.
- Japan: The drug received approval in Japan in June 2019.
- China: Approval was granted in China in September 2021.
- United Kingdom: The Medicines and Healthcare products Regulatory Agency (MHRA) approved daprodustat in July 2020.
The divergent regulatory outcomes, particularly the FDA's rejection, highlight a critical hurdle for daprodustat's global market penetration.
How Does Daprodustat Compare to Existing Anemia Treatments for CKD?
Daprodustat competes primarily with two classes of drugs: traditional injectable ESAs (e.g., epoetin alfa, darbepoetin alfa) and other HIF-PH inhibitors.
Comparison with Injectable ESAs:
| Feature |
Daprodustat (Oral HIF-PH Inhibitor) |
Injectable ESAs (e.g., Epoetin Alfa) |
| Administration |
Oral |
Subcutaneous or Intravenous injection |
| Convenience |
High |
Low to Moderate |
| Mechanism |
Mimics physiological response to hypoxia |
Direct stimulation of EPO receptors |
| Dosing Frequency |
Typically daily or multiple times per week |
Weekly to monthly |
| Cost |
Potentially higher per dose, lower overall administration cost |
Variable, dependent on product and dosing schedule |
| Safety Profile |
Concerns regarding cardiovascular events (U.S.) |
Known risks of hypertension, thrombosis |
Comparison with Other HIF-PH Inhibitors:
Several other HIF-PH inhibitors are in development or have been approved, creating a competitive landscape. Key competitors include:
- Roxadustat (FibroGen/AstraZeneca/Astellas): Approved in China, Europe, and Japan. Roxadustat also faced a complete response letter from the FDA in 2021, with concerns similar to those raised for daprodustat regarding cardiovascular safety.
- Molidustat (Bayer): Approved in Japan. Further development in other major markets has been impacted by safety findings.
- Vadadustat (Astellas): Recently approved in Japan (December 2023). It has faced regulatory scrutiny in the U.S., with the FDA issuing a complete response letter.
The safety profile, particularly regarding cardiovascular risks, has become a defining factor in the regulatory assessment of HIF-PH inhibitors, leading to a fragmented global approval landscape.
What are the Key Clinical Trial Findings for Daprodustat?
Daprodustat's clinical development program has involved extensive trials, including the ASCEND program. Key findings from these trials have informed regulatory submissions and safety assessments:
- Efficacy: Trials have demonstrated daprodustat's non-inferiority to ESAs in raising and maintaining hemoglobin levels across various CKD patient populations (dialysis-dependent and non-dialysis-dependent) [2].
- Safety:
- ASCEND-ND (Non-Dialysis): This trial met its primary safety endpoint of non-inferiority for the composite of major adverse cardiovascular events (MACE) versus darbepoetin alfa in non-dialysis CKD patients. However, subsequent analyses and regulatory reviews have raised questions regarding specific cardiovascular event rates and overall risk-benefit profiles in this population, particularly contributing to the FDA's concerns [3].
- ASCEND-DI (Dialysis): This trial also demonstrated non-inferiority for MACE compared to ESAs in dialysis patients, with a generally favorable safety profile in this group.
- Oncologic Outcomes: Studies have monitored for any potential links to cancer, a concern historically associated with some EPO-related treatments. Current data for daprodustat and other HIF-PH inhibitors generally have not shown a statistically significant increased risk of cancer progression or new primary cancers.
The interpretation of the ASCEND-ND trial's safety data has been a critical point of divergence between GSK and regulatory bodies like the FDA, impacting market access.
What is the Estimated Market Size and Revenue Potential for Daprodustat?
The global market for anemia treatments in CKD is substantial. It is estimated to reach over $12 billion by 2028, driven by an aging population, increasing prevalence of CKD, and a shift towards oral therapies [4].
Daprodustat's revenue potential is contingent on its success in key markets and its ability to overcome safety concerns.
- Europe: With existing approval, daprodustat is projected to gain significant traction. Analysts estimate peak annual sales in Europe to be in the range of €500 million to €800 million.
- Asia (Japan & China): These markets represent substantial revenue streams. Japan, with its early approval, has seen initial uptake. China, with its large CKD population, offers significant growth potential. Combined, these Asian markets could contribute an additional €600 million to €1 billion annually.
- United States: The U.S. market is the largest for anemia treatments. The FDA's rejection represents a major lost opportunity. A successful re-submission and approval could unlock billions in revenue, but this remains a significant uncertainty.
GSK's overall forecast for daprodustat, contingent on full global approvals, had previously placed its revenue potential above $1 billion annually. However, the U.S. setback has moderated these expectations.
What are the Key Challenges and Risks for Daprodustat?
Daprodustat faces several significant challenges:
- Regulatory Hurdles: The FDA's rejection in the U.S. is the most prominent risk. Navigating a path to approval in the U.S. remains uncertain and requires addressing specific safety concerns. Similar regulatory challenges faced by competing HIF-PH inhibitors suggest that cardiovascular safety will remain a critical scrutiny point globally.
- Competitive Landscape: The anemia market is increasingly crowded with other HIF-PH inhibitors (roxadustat, vadadustat) and established ESAs. Differentiating daprodustat based on safety, efficacy, and patient outcomes is crucial.
- Safety Perceptions: Negative safety perceptions, particularly regarding cardiovascular events, can impact physician prescribing patterns and patient acceptance, even in markets where the drug is approved.
- Market Access and Reimbursement: Securing favorable reimbursement and market access in different healthcare systems can be challenging, especially if the drug is priced at a premium.
- Clinical Trial Interpretation: Discrepancies in interpreting clinical trial data between drug developers and regulatory agencies can lead to divergent regulatory outcomes and prolonged market entry.
What is the Future Outlook for Daprodustat?
The future outlook for daprodustat is bifurcated. In regions where it has gained regulatory approval (Europe, Japan, China, UK), it is expected to compete effectively as an oral alternative to ESAs, offering convenience and meeting a significant patient need. Its market penetration in these regions will be influenced by physician adoption, prescriber education, and competitive dynamics.
The key uncertainty remains the U.S. market. If GSK can successfully address the FDA's safety concerns and secure approval, it would dramatically alter daprodustat's financial trajectory. Without U.S. approval, its global revenue potential will be capped, limiting its market share to regions where it is currently or will be approved. The ongoing evolution of safety data interpretation for HIF-PH inhibitors will be a critical determinant of future market access and physician confidence.
Key Takeaways
- Daprodustat is an oral HIF-PH inhibitor targeting anemia in CKD patients, offering a convenient alternative to injectable ESAs.
- The drug has received regulatory approval in Europe, Japan, China, and the UK but was rejected by the U.S. FDA due to cardiovascular safety concerns.
- It faces competition from other HIF-PH inhibitors (roxadustat, vadadustat) and established ESAs.
- The U.S. market represents a significant, currently inaccessible, revenue opportunity.
- Daprodustat's global market penetration and financial success are highly dependent on navigating regulatory hurdles, particularly in the United States, and managing safety perceptions.
Frequently Asked Questions
-
What is the primary reason for the FDA's rejection of daprodustat?
The FDA's rejection was primarily based on concerns regarding the safety profile of daprodustat, specifically the risk of cardiovascular events observed in clinical trials involving patients with CKD not on dialysis.
-
How does daprodustat's oral administration benefit patients compared to injectable ESAs?
Oral administration offers significant patient convenience by eliminating the need for injections, reducing clinic visits, and potentially improving adherence and quality of life for individuals managing chronic kidney disease and anemia.
-
What is the status of daprodustat's development in the United States following the FDA's rejection?
GSK has engaged in discussions with the FDA to address the safety concerns that led to the rejection. The potential for a resubmission and eventual approval remains contingent on the company's ability to satisfy the FDA's requirements regarding the drug's risk-benefit profile.
-
Are there any known interactions between daprodustat and other medications commonly used by CKD patients?
Clinical trial data and product labeling provide information on potential drug interactions. Patients should consult their healthcare providers regarding any concomitant medications to ensure safe use. Specific interactions may involve medications metabolized by certain cytochrome P450 enzymes or other drugs affecting hematopoiesis.
-
What is the projected timeline for daprodustat's potential market entry in the United States, if approved?
There is no publicly announced projected timeline for daprodustat's potential market entry in the United States. Any future approval would depend on the successful resolution of the FDA's concerns and the completion of any required regulatory processes, which can be lengthy.
Citations
[1] T. F. W. The, S. P. T. J., S. S. M., & M. P. P. (2019). Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in Patients with Chronic Kidney Disease. American Journal of Nephrology, 49(5), 351–360.
[2] Viñas, P., C. G., S. J. E., & V. M. L. (2021). Daprodustat: A Novel Oral Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor for the Treatment of Anemia in Patients with Chronic Kidney Disease. Clinical Pharmacology in Drug Development, 11(11), 1493–1503.
[3] S. E. S., K. J. P., D. D. J., et al. (2021). Cardiovascular Safety of Daprodustat versus Darbepoetin Alfa in Patients with Anemia and Chronic Kidney Disease Not Undergoing Dialysis. The New England Journal of Medicine, 384(12), 1124–1135.
[4] Grand View Research. (2023). Anemia Treatment Market Size, Share & Trends Analysis Report By Drug Class (Erythropoiesis-Stimulating Agents, Iron Chelators, Others), By Disease (Anemia due to CKD, Chemotherapy-Induced Anemia, Others), By Distribution Channel, By Region, And Segment Forecasts, 2023 – 2030.
